TROP2 update: dato takes and x-reads in TNBC/NSCLC

Research evidence excerpt

TROP2 update: dato takes and x-reads in TNBC/NSCLC

Deutsche Bank Group

Deutsche Numis Research

Rating Company Date

Sell AstraZeneca 25 June 2026

Company Update

Europe

United Kingdom

Reuters Bloomberg Exchange Ticker Price at 24 Jun 2026 (GBP) 13,910.00

AZN.L AZN LN LSE AZN

Price Target (GBP) 11,500.00

Pharmaceuticals

15,542.00 -

Pharmaceuticals 52-week range (GBP) 10,120.00

TROP2 update: dato takes and x-reads

Valuation & Risks in TNBC/NSCLC

Emmanuel Papadakis, Ph.D., CFA

Summary takes Research Analyst

It’s been some time since our last detailed comment on Datroway, the subject of +44-20-754-18522

one of two key H2 oncology readouts on which we remain cautious (i.e. the

Niall Alexander

AVANZAR trial in NSCLC). Here we take the opportunity to briefly comment on a Research Analyst

handful of relevant items, comprising x-read on th A03/A04 Trodelvy approvals last +44-20-754-12185

night coupled with recent physician feedback on the recent TB02 approval in 1L

Henrietta Boeg

TNBC plus the x-read on a recent GILD/MRK trial miss (EVOKE-03) for AZN’s

Research Associate

pending trials in NSCLC (i.e. AVANZAR/TL07/TL08). Bottom line, it leaves us largely

+44-20-754-10119

reaffirmed in our cautious perspective on the outlook for both trial outcomes and

potential modest pressure on consensus (DB/cons dato AZN sales+collab 2030E Kate Farrelly

$1.3bn/$1.7bn respectively). Research Associate

Summary takes on TNBC approval and feedback Shashindra Seresinhe

n Datroway’s TB02 was FDA-approved 22nd May for the c50% PD-ineligible

1L TNBC patients; a subsequent snap 3rd party poll of 115 US (30 US/85

EU) oncologists issued a week ago showed around half viewed the Supun Ukwatta

approval as “an important new option” with only around a quarter viewing Research Associate